Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren Phase 2a in Nonambulatory Nonsense-Mutation DMD/BMD
NCT01009294Phase 2Terminated
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jan 2010
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ataluren in Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), sponsored by PTC Therapeutics, Inc.. Started Jan 2010; status: terminated.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on NCT01009294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01009294.